Geron mit Hammernews!! (Seite 300)

[meislo]

Warum geht es so abwärts mit Geron?

Vielleicht liegt hier die Antwort verborgen

Reuters
EntreMed Up on Experimental Cancer Drug
Wednesday April 23, 11:37 am ET


NEW YORK (Reuters) - Shares of EntreMed Inc. (NasdaqNM:ENMD - News) soared for the second straight day on Wednesday after the biotechnology company said its experimental cancer drug blocks a protein linked to several types of cancer.
ADVERTISEMENT


The shares were up as much as 52 percent after more than doubling on Tuesday.

On Tuesday, EntreMed said tests of its Panzem drug in animals confirmed that its anti-cancer activity stems, in part, from its ability to inhibit production of a protein called hypoxia inducible factor 1, or HIF.

The human body produces too much HIF in more than 70 percent of cancers, including breast cancer, prostate cancer, brain cancer, lung cancer and head and neck cancers, according to the company.

EntreMed said it would continue developing Panzem for cancer and would consider testing it against other disorders linked with HIF, including arthritis and heart disease.

EntreMed shares were up $1.22, or 44 percent, at $3.97 in late-morning trading on the Nasdaq stock market after soaring as high as $4.19 earlier in the session.


Die Charttechnik lässt auch ungemach befürchten da sich eine SKS-Formation enrwickelt hat.Aber ich bin nur Laie in der Interpretation von Charts

gruss meislo

[edgar99]

test

[meislo]

Wieder ein neues Patent für geron?
Ist offiziel von geron noch nicht bestätigt
Was meint Ihr?

United States Patent 6,551,774
West , et al. April 22, 2003

--------------------------------------------------------------------------------
Diagnostic methods for conditions associated with elevated cellular levels of telomerase activity


Abstract
Method and compositions are provided for the determination of telomere length and telomerase activity, as well as the ability to increase or decrease telomerase activity in the treatment of proliferative diseases. Particularly, primers are elongated under conditions which minimize interference from other genomic sequences, so as to obtain accurate determinations of telomeric length or telomerase activity. In addition, compositions are provided for intracellular inhibition of telomerase activity and means are shown for slowing or reversing the loss of telomeric repeats in aging cells.


--------------------------------------------------------------------------------
Inventors: West; Michael D. (San Carlos, CA); Harley; Calvin B. (Palo Alto, CA); Weinrich; Scott L. (San Francisco, CA); Strahl; Catherine M. (San Francisco, CA); McEachern; Michael J. (San Francisco, CA); Shay; Jerry (Dallas, TX); Wright; Woodring E. (Arlington, TX); Blackburn; Elizabeth H. (San Francisco, CA); Kim; Nam Woo (Sunnyvale, CA); Vaziri; Homayoun (Toronto, CA)
Assignee: Board of Regents, The University of Texas System (Dallas, TX); The Regents of the University of California (Oakland, CA); Geron Corporation (Menlo Park, CA)
Appl. No.: 378535
Filed: August 20, 1999


Hier der Link

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=H…


gruss meislo

[meislo]

DJ Millennium Partners Has 8.45% Passive Stake In Geron GERN


16:57 ET

DJ Millennium Partners Has 8.45% Passive Stake In Geron
18 Apr 16:57

WASHINGTON (Dow Jones)--Millennium Partners L.P. reported holding an 8.45%
stake in Geron Corp. (GERN), according to a Schedule 13G filed Friday with the
Securities and Exchange Commission.

On April 8, Millennium Partners beneficially owned 2.5 million Geron common
shares, including 300,000 shares issuable when certain warrants are exercised.

On April 8 Geron said in a press release that it agreed to sell 4 million
common shares in a private placement to two investors at $4.60 a share. The
investors also received warrants to buy an additional 600,000 shares at $6.34 a
share.

A Schedule 13G denotes a passive investment stake in a company. Filers aren`t
required to provide a reason for any changes in stake and aren`t required to
detail any transactions.

Geron is a biopharmaceutical company that discovers, develops and markets
therapeutic and diagnostic products for applications in oncology, drug
discovery and regenerative medicine.

Shares of the company closed Thursday at $4.69, up 12 cents.

-By Todd Goren, Dow Jones Newswires; 202-628-9782; [e-mail]

(END) Dow Jones Newswires
04-18-03 1657ET

[meislo]

Es scheint so zu sein, das Kursgewinne aufgrund Meldungen von Patententscheiden, wieder einmal nach ein paar Börsentagen vollständig abgegeben werden

gruss meislo

[KMS]

Schon wieder ein Patent für GERON.
Mal sehn was der Kurs macht.

KMS

[js200]

04/16/2003 (07:30 ET) Geron Corporation Announces Issuance of U.S. Patent for Pig Cloning - Business Wire
04/15/2003 (14:10 ET) DEF 14A: GERN El Dir; Inc Stk Opt Pln; Inc Emp Stk Pln - Knobias
04/15/2003 (13:58 ET) New DEF 14A just released for GERN - Edgar
04/15/2003 (07:32 ET) Geron Receives U.S. Patent Covering Use of Telomerase Inhibitors in Patients - Business Wire
04/11/2003 (17:04 ET) New SC 13G just released for GERN - Edgar

JS200

[js200]

Geron Corporation Announces Issuance of U.S. Patent for Pig Cloning
via COMTEX

April 16, 2003

MENLO PARK, Calif., Apr 16, 2003 (BUSINESS WIRE) --

Geron Corporation (Nasdaq:GERN) announced today that it has been issued U.S. Patent No. 6,548,741, describing an improved method for cloning pigs.

The inventors include some of the original scientists at the Roslin Institute in Edinburgh, Scotland, who cloned Dolly the sheep. The new patent teaches how the Dolly method can be adapted to clone pigs more efficiently by maturing the recipient pig oocyte using defined culture conditions. The patented new method results in cloned pig embryos with improved developmental potential.

This is the first U.S. patent assigned directly to Geron Corporation relating to animal cloning. Geron also owns exclusive rights to the Roslin patents (U.S. Patent Nos. 6,147,276, 6,252,133 and 6,525,243), which cover the fundamental nuclear transfer technology used in cloning animals.

Thomas B. Okarma, Ph.D., M.D., Geron`s president and chief executive officer, explained, `We entered into the collaboration with the Roslin Institute in order to develop and consolidate the field of animal cloning, as well as to support our regenerative medicine program. Cloned pigs are of interest because of their potential to provide much needed organs for xenotransplantation. This new patent is an important addition to our nuclear transfer intellectual property portfolio. It improves prospects for commercialization of the cloning process for pigs. We have licensed rights or granted options to the fundamental cloning process to six companies, and are in discussions with others regarding additional licenses.`

Professor John Clark, at the Roslin Institute, said, `This patent adds to the nuclear transfer portfolio initially generated at the Roslin Institute and enhanced in collaboration with Geron Corporation. Xenotransplantation has important medical potential. The patented new methods enhance the likelihood of commercially successful organ replacement therapies.`

Geron Corporation is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic products for applications in oncology and regenerative medicine, and research tools for drug discovery. Geron`s product development programs are based upon three patented core technologies: telomerase, human embryonic stem cells, and nuclear transfer.

This news release may contain forward-looking statements made pursuant to the `safe harbor`provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding future applications of Geron Corporation`s technology constitute statements involving risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products and the maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Geron`s periodic reports, including the annual report on Form 10-K for the year ended December 31, 2002.

Geron Corporation David L. Greenwood, 650/473-7765 (Investor and Media Relations)

http://www.businesswire.com

Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.

Copyright (C) 2003 Business Wire. All rights reserved.

JS200

[meislo]

Geron Corp. gewann ein Patent für den Gebrauch der Oligonucleotidedrogen, wenn er telomerase, ein Enzym blockierte, das Krebszellen veranläßt, sich unbestimmt zu teilen. In einem Pressekommuniqué Dienstag, sagte das biotechunternehmen, daß es telomerasehemmnisse dieser Art studiert, einschließlich seines Mittels GRN163, in der preclinical Arbeit als möglicher Behandlung für eine Strecke der Krebse. Anteile REKLAMEANZEIGEHERAUF Geron stiegen auf die Nachrichten und vor kurzem handelten 48 Cents oder 10,9%, an $ 4,88 auf schwerer Nasdaq-Ausgabe von 2,3 Million Anteilen. Durchschnittliche Ausgabe ist ungefähr 1,5 Million Anteile ein Tag. Geron sagte, daß es das erste zum Klonen des RNS-Bestandteils des menschlichen telomerase war. Die Firma empfing vorher Patente für diese RNS sowie die Oligonucleotidemittel, die auf seiner Reihenfolge basierten. Geron sagte, daß das neueste Patent wichtig ist, weil es ausdrücklich den Gebrauch jener Oligonucleotides umfaßt, Krebspatienten zu behandeln. Die besagte Firma sein GRN163 ist ein spezifisches und ungiftiges Hemmnis von telomerase, das gegen alle menschlichen Tumorhauptsächlicharten in vitro und in den Tiermodellen des menschlichen Gehirns, der Prostata, des Lymphoms, des myeloma und der zervikalen Krebse aktiv ist. Geron merkte, daß anders als viele Krebsdrogen, das Mittel Giftigkeit nicht in den Tieren an den therapeutisch wirkungsvollen Dosen verursacht hat. Geron, das Einkommen von $1,2 Million letztes Jahr bekanntgab, leitet weitere Giftigkeituntersuchungen über GRN163, um Weise für die Archivierung einer neuen Drogeuntersuchungsanwendung für die Behandlung des Gehirnkrebses zu bilden. Letzter August, empfing die Firma ein Patent für eine Therapie, die telomerase verwendet, um das immune System eines Patienten vorzubereiten, um Krebszellen zu erkennen und zu zerstören.


Geron Corp Gets Patent for Oligonucleotide Drugs
Tuesday April 15, 10:45 am ET


MENLO PARK, Calif. (Dow Jones)--Geron Corp. won a patent for the use of oligonucleotide drugs in blocking telomerase, an enzyme that causes cancer cells to divide indefinitely.
In a press release Tuesday, the biotech firm said it is studying telomerase inhibitors of this type, including its GRN163 compound, in preclinical work as a potential treatment for a range of cancers.

ADVERTISEMENT


Geron shares rose on the news and recently traded up 48 cents, or 10.9%, at $ 4.88 on heavy Nasdaq volume of 2.3 million shares. Average volume is about 1.5 million shares a day.

Geron said it was the first to clone the RNA component of human telomerase. The company previously received patents for that RNA as well as oligonucleotide compounds based on its sequence. Geron said the latest patent is important because it explicitly covers the use of those oligonucleotides to treat cancer patients.

The company said its GRN163 is a specific and nontoxic inhibitor of telomerase that is active against all major human tumor types in vitro and in animal models of human brain, prostate, lymphoma, myeloma and cervical cancers. Geron noted that unlike many cancer drugs, the compound hasn`t caused toxicity in animals at therapeutically effective doses.

Geron, which posted revenue of $1.2 million last year, is conducting further toxicity studies on GRN163 to make way for the filing of an investigational new drug application for the treatment of brain cancer.

Last August, the company received a patent for a therapy that uses telomerase to prime a patient`s immune system to recognize and destroy cancer cells.

[meislo]

Patenterteilung bedeutet in der Regel für eine betroffene Aktie aus dem Stammzellemmillieu starke Kursausschläge in der Regel 30-60% aber mit der Folge, diese Gewinne innerhalb weniger Börsentage meist vollständig wieder abzugeben. Bei Geron stellt sich die Situation nun aber etwas anders dar und zwar nur aus einem Grund!! Die Aktie ist seit März aus ihrer 3-jährigen Talfahrt unter hohem Volumen ausgebrochen und befindet sich nun in einem neuen Aufwärtstrend. Wie sich in einem solchen Fall Patententscheidungen zugunsten einer Aktie nachhaltig auf den Kurs auswirkt bleibt abzuwarten!!

gruss meislo